Enzalutamide: Discovery, Development, Safety and Pharmacovigilance

MDV3100 discovery, androgen-receptor biology, AFFIRM, PREVAIL, PROSPER, ARCHES, ENZAMET and EMBARK; current US/EU authorisations; seizures, cardiovascular and fracture risks, dysphagia, digoxin assay interference and practical pharmacovigilance.

Take test

Enzalutamide: Discovery, Development, Safety and Pharmacovigilance

Enzalutamide is an orally administered androgen-receptor (AR) inhibitor whose development changed the treatment of advanced prostate cancer and subsequently several earlier disease states. Its history illustrates a particularly instructive translational path: understanding why prostate tumours escape older hormonal treatment led to a drug that blocks AR signalling more effectively under conditions of receptor overexpression. Later trials demonstrated benefits in metastatic castration-resistant disease, nonmetastatic castration-resistant disease, metastatic hormone-sensitive disease and selected patients with high-risk biochemical recurrence [1–5].

These expansions also changed the safety question. The treated population includes older patients with competing cardiovascular and neurological risks, patients exposed for years, and patients whose cancer has not yet become radiographically metastatic. Assessment therefore requires precise disease-state classification, the relevant trial endpoint, concomitant androgen-deprivation therapy (ADT), and the marketed formulation. This article uses the international nonproprietary name enzalutamide throughout; Xtandi is the originator brand rather than a separate active substance.

1. Why androgen-receptor signalling remains important after castration

The androgen receptor is a ligand-activated nuclear transcription factor. Testosterone and its more potent metabolite dihydrotestosterone bind the receptor, enabling signalling that supports prostate-cell growth and survival. Androgen-deprivation therapy lowers circulating androgen availability through medical or surgical approaches, but it does not necessarily eliminate tumour reliance on the AR pathway. Castration-resistant prostate cancer (CRPC) is defined by progression despite a castrate hormonal environment, not by proof that androgen signalling has become irrelevant.

Tumours may adapt through AR amplification or overexpression, changes in steroid synthesis, receptor variants and alternative survival pathways. Not every resistant tumour shares the same mechanism. A drug aimed at the AR can therefore remain effective after testosterone suppression, but clinical benefit cannot be assumed for every resistance phenotype. This biological distinction helps explain why enzalutamide is not interchangeable with ADT in most authorised metastatic and CRPC settings [1,4,5].

2. Discovery: from resistance biology to MDV3100

Work by Charles Sawyers and collaborators established that increased AR expression could turn some earlier antiandrogens into less effective inhibitors, or even produce agonist-like effects in experimental models. The resulting medicinal-chemistry programme, undertaken with Michael Jung and colleagues at UCLA, sought antagonists retaining activity when AR expression was elevated. Preclinical work described RD162 and MDV3100, the compound subsequently named enzalutamide [4,5].

The 2009 report by Tran and colleagues demonstrated receptor binding, reduced nuclear translocation, impaired AR interaction with DNA and coactivators, and antitumour effects in experimental systems. These were mechanistic and early clinical findings—not evidence of established survival benefit in the eventual authorised populations. The clinical development programme then tested whether this biology translated into outcomes meaningful to patients [5].

The United States first approved enzalutamide in 2012, initially in a narrower advanced-disease setting. European Union marketing authorisation followed on 21 June 2013. Subsequent regulatory extensions depended on separate randomised evidence in distinct disease states; they should not be represented as one original broad approval [1–3].

3. Mechanism, metabolism and exposure

Enzalutamide inhibits AR signalling at multiple steps, including androgen binding, receptor nuclear translocation and downstream transcriptional activity. It is not a cytotoxic chemotherapy agent and does not itself achieve surgical castration. Its pharmacology explains why it can be combined with testosterone-suppressing therapy in indicated settings [1,5].

After oral administration, enzalutamide is extensively metabolised, including to the active metabolite N-desmethyl enzalutamide. The US label describes a long elimination half-life and accumulation during repeated dosing. Pharmacokinetic persistence matters when assessing adverse-event onset, dechallenge and interactions: stopping a medicine does not necessarily terminate pharmacological effects immediately [1].

A distinctive feature is its enzyme-interaction profile. Enzalutamide is a strong CYP3A4 inducer and a moderate CYP2C9 and CYP2C19 inducer, potentially lowering exposure to susceptible concomitant medicines. Conversely, strong CYP2C8 inhibitors can increase enzalutamide exposure, while strong CYP3A4 inducers can reduce it. This creates two different clinical problems—loss of effect of a co-medication versus altered exposure to enzalutamide—which require different causal analyses [1].

4. Clinical language: four states that must not be conflated

State Clinical meaning Why the distinction matters
Metastatic CRPC Metastatic progression despite castrate testosterone Earlier pivotal trials were in patients before or after docetaxel
Nonmetastatic CRPC No metastases on the trial's conventional imaging, with castration resistance PROSPER selected patients at high risk by PSA doubling time
Metastatic hormone-sensitive prostate cancer Metastatic cancer still responsive to androgen suppression ARCHES/ENZAMET assessed intensification alongside testosterone suppression
Nonmetastatic hormone-sensitive high-risk biochemical recurrence PSA relapse after local treatment without metastases in a selected high-risk group EMBARK studied enzalutamide with or without leuprolide and a prespecified treatment-pause strategy

The labels hormone-sensitive/castration-sensitive and castration-resistant describe treatment context, not simply tumour stage. The imaging method used to classify nonmetastatic disease matters: contemporary PSMA PET can reveal lesions missed by conventional imaging, so trial eligibility and clinical extrapolation must be considered carefully [1–3,8,12].

5. From metastatic CRPC to earlier disease: pivotal trials

AFFIRM: survival after docetaxel

The phase 3 AFFIRM trial randomised 1,199 patients with metastatic CRPC previously treated with docetaxel to enzalutamide or placebo. Median overall survival was 18.4 versus 13.6 months, respectively (hazard ratio [HR] for death 0.63, 95% confidence interval [CI] 0.53–0.75). This was direct evidence of survival benefit in a previously treated metastatic population, not evidence that all prostate cancers should receive enzalutamide [6].

The study was stopped after a planned interim analysis. As with other trials in advanced cancer, subsequent therapies and selection criteria are relevant when applying the median survival figures to individual patients. The trial also established an important safety-development issue: seizures were reported in some treated patients, prompting further characterisation of neurological risk [1,6].

PREVAIL: metastatic CRPC before chemotherapy

PREVAIL enrolled 1,717 chemotherapy-naĂŻve patients with metastatic CRPC and demonstrated benefit for both radiographic progression-free survival and overall survival. At 12 months, radiographic progression-free survival was 65% with enzalutamide versus 14% with placebo, with HR 0.19 for radiographic progression or death in the reported analysis [7]. These estimates belong to this trial's imaging schedule, endpoint definition and baseline disease state.

The shift from AFFIRM to PREVAIL was not merely a change in line of therapy: it broadened exposure to patients who could remain on treatment for longer before requiring chemotherapy. That longer treatment horizon increases the practical importance of fatigue, falls, comedication interactions and cardiovascular risk.

PROSPER: nonmetastatic castration-resistant disease

PROSPER enrolled 1,401 patients with nonmetastatic CRPC, continuing ADT and a PSA doubling time of 10 months or less. Median metastasis-free survival was 36.6 months with enzalutamide and 14.7 months with placebo (HR 0.29, 95% CI 0.24–0.35) in the primary analysis [8]. This was a metastasis-free survival result; it should not be silently relabelled as an overall-survival result.

A later prespecified overall-survival analysis reported median survival 67.0 versus 56.3 months, HR 0.73 (95% CI 0.61–0.89) [9]. The distinction between an early surrogate or intermediate endpoint and later survival evidence is important for accurate regulatory and clinical teaching. “Nonmetastatic” was defined using the trial's imaging approach, not a claim that occult microscopic or PSMA PET-detectable disease could not exist.

ARCHES and ENZAMET: metastatic hormone-sensitive disease

In ARCHES, 1,150 men with metastatic hormone-sensitive prostate cancer were assigned to enzalutamide plus ADT or placebo plus ADT. The primary endpoint was radiographic progression-free survival: HR 0.39 (95% CI 0.30–0.50) in the primary report, with median not reached in the enzalutamide arm versus 19.0 months in the placebo arm [10]. The comparator was ADT in both arms; the result does not imply that enzalutamide replaced androgen deprivation.

ENZAMET asked a related but different question: testosterone suppression plus enzalutamide versus testosterone suppression plus a standard nonsteroidal antiandrogen, in an open-label design that also allowed planned early docetaxel. The first report showed an overall-survival advantage (HR 0.67, 95% CI 0.52–0.86) but also more adverse-event discontinuations and reported seizures in the enzalutamide group [11]. Its comparator and concurrent-treatment structure differ from ARCHES, so pooling the headlines without qualification would be misleading.

EMBARK: high-risk biochemical recurrence after local treatment

EMBARK studied 1,068 patients with nonmetastatic hormone-sensitive prostate cancer and high-risk biochemical recurrence after definitive local therapy. Participants received enzalutamide plus leuprolide, leuprolide alone or enzalutamide monotherapy. The 2023 primary analysis reported five-year metastasis-free survival of 87.3%, 71.4% and 80.0%, respectively. Compared with leuprolide alone, HR was 0.42 for the combination and 0.63 for monotherapy [12].

The October 2025 overall-survival analysis adds an essential qualification. Eight-year overall survival was 78.9% with enzalutamide plus leuprolide versus 69.5% with leuprolide alone, HR for death 0.60 (95% CI 0.44–0.80). Enzalutamide monotherapy yielded 73.1% eight-year overall survival and was not statistically superior to leuprolide alone for this endpoint (HR 0.83, 95% CI 0.63–1.10) [13]. It would therefore be inaccurate to claim that both enzalutamide strategies demonstrated the same survival advantage. The 2023 metastasis-free survival results and 2025 overall-survival results answer different questions.

EMBARK incorporated treatment suspension in patients meeting a prespecified PSA response criterion. The July 2026 US label describes the corresponding interruption and reinitiation conditions for its high-risk biochemical-recurrence indication [1]. These are specific to that setting; they are not a generic intermittent schedule for every patient receiving enzalutamide.

6. How to read the evidence without overgeneralising

Trial Population Key reported endpoint Interpretation boundary
AFFIRM Post-docetaxel metastatic CRPC Overall survival Previously treated advanced disease
PREVAIL Pre-chemotherapy metastatic CRPC Radiographic PFS and overall survival Different line and treatment duration
PROSPER High-risk nonmetastatic CRPC Metastasis-free survival; later overall survival Conventional imaging and rapid PSA rise
ARCHES Metastatic hormone-sensitive Radiographic PFS Both arms received ADT
ENZAMET Metastatic hormone-sensitive Overall survival Active comparator; docetaxel subgroup context
EMBARK High-risk biochemical recurrence Metastasis-free survival; later overall survival Combination survival benefit; monotherapy OS not significant

An HR is a relative time-to-event comparison, not an individual probability or an absolute percentage reduction. Median survival, time to metastasis and radiographic progression-free survival are not interchangeable. Trial adverse-event proportions may also differ because follow-up duration, baseline risk, ascertainment and concomitant therapy differ [6–13].

The figure decision for this article is to use the evidence-state matrix above rather than a flow diagram: the populations are partly overlapping biological states, not an obligatory linear treatment sequence. A simple arrow diagram could wrongly imply that every patient traverses each stage or receives each regimen.

7. Regulatory status and treatment context in 2026

The European Commission's Union Register identifies Xtandi as authorised for metastatic hormone-sensitive prostate cancer with ADT; high-risk nonmetastatic CRPC; two metastatic CRPC situations distinguished by prior docetaxel and chemotherapy suitability; and high-risk nonmetastatic hormone-sensitive biochemical recurrence in men unsuitable for salvage radiotherapy, as monotherapy or with ADT [2,3]. The EMA's current English product information was updated 29 July 2026. The public EPAR overview is useful orientation but should not replace the current Summary of Product Characteristics (SmPC) for clinical particulars.

The US DailyMed Xtandi label updated 28 July 2026 covers CRPC, metastatic castration-sensitive prostate cancer, and nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis [1]. It lists 160 mg once daily as the recommended dose and differentiates requirements for concurrent GnRH analogue or prior bilateral orchiectomy in CRPC/metastatic castration-sensitive disease from the optional GnRH analogue in the specified high-risk biochemical-recurrence setting. It also describes dose modification for intolerance and interactions. These are US product instructions, not a universal EU dosing or reimbursement policy.

Regulatory authorisation, national access/reimbursement, guideline preference and trial evidence are different categories. For example, an authorised high-risk biochemical-recurrence indication does not imply that all patients with any PSA rise after surgery are eligible. Salvage-radiotherapy suitability, risk stratification and disease imaging remain clinically material [1–3,12,13].

8. Neurological safety: seizures and PRES

The current US label reports seizures in 0.6% of patients receiving enzalutamide across eight randomised trials; most trials generally excluded patients with recognised predisposing factors. In a separate single-arm study enrolling patients with risk factors, 8 of 366 (2.2%) experienced seizures. The different populations and designs mean that these percentages should not be compared as if they were randomised estimates of the effect of pre-existing risk factors [1].

A medically useful seizure case records previous seizures, cerebrovascular disease, brain lesions, head injury, concurrent medicines affecting seizure threshold, electrolyte or metabolic disturbance, precise episode description, investigations and temporal exposure. The US label directs permanent discontinuation after a seizure during treatment. This is a labelled action, not merely an editorial suggestion [1].

Posterior reversible encephalopathy syndrome (PRES) is a distinct serious neurological syndrome that may include acute confusion, visual disturbance, headache, seizures and hypertension. Diagnosis generally requires appropriate brain imaging, preferably MRI, rather than coding PRES from a headache alone. The US label directs discontinuation if PRES develops [1]. A pharmacovigilance narrative should distinguish confirmed radiological PRES from a suspected syndrome awaiting investigation.

9. Cardiovascular events, hypertension, falls and fractures

In the US label's pooled five placebo-controlled trials, ischaemic heart disease occurred in 3.5% versus 2.0% of patients receiving enzalutamide and placebo; grade 3–4 ischaemic events occurred in 1.8% versus 1.1% [1]. These are trial proportions within the specified pooled data, not estimates of risk in every age group or treatment combination. The label advises optimisation of cardiovascular risk factors and discontinuation for grade 3–4 ischaemic heart disease.

Falls occurred in 12% versus 6% and fractures in 13% versus 6% in the same pooled placebo-controlled context [1]. These outcomes are clinically meaningful in patients who may already have reduced bone health because of age, metastatic bone disease or ADT. The observed events cannot all be attributed exclusively to enzalutamide without considering those competing contributors. Clinical evaluation includes baseline mobility, previous falls, orthostatic symptoms, bone health, sedatives, comorbidities, fracture site and the relationship to cancer progression.

Hypertension, fatigue, musculoskeletal pain, hot flushes, decreased appetite and cognitive or attention changes also affect treatment persistence and quality of life. Distinguish symptom burden from serious medically confirmed diagnoses. The relevant comparator and duration of observation should accompany any quoted frequency [1,2,14].

10. Hypersensitivity, swallowing safety and physical product design

The US label identifies hypersensitivity reactions including swelling of the face, lips or tongue; pharyngeal oedema has also been reported after marketing [1]. Anaphylaxis or airway-threatening swelling warrants urgent medical care and precise clinical documentation. The label distinguishes temporary interruption during evaluation from permanent discontinuation for serious hypersensitivity.

Severe dysphagia or choking associated with product size is a particularly important formulation-related warning. The July 2026 US label advises swallowing capsules or tablets whole with sufficient water; it explicitly says not to open capsules or cut, crush or chew tablets. Smaller available tablets may be considered for patients having difficulty swallowing, and treatment should be discontinued if the patient cannot swallow the product [1]. This is not a licence to improvise crushing or feeding-tube administration.

A choking report should record the exact capsule/tablet strength, whether the product was swallowed intact, swallowing history, the circumstances of administration, any aspiration, emergency intervention and outcome. The event may be a product-use problem rather than a systemic pharmacological reaction. The same INN can have distinct formulation-related safety risks, making brand/presentation traceability necessary even in a one-INN article.

11. Reproductive and long-term safety considerations

Enzalutamide is not indicated for women, and animal data plus its mechanism support an embryo-fetal toxicity warning. The US label advises men with female partners of reproductive potential to use effective contraception during treatment and for three months after the last dose [1]. This duration is product-specific label information, not a general rule for all oncology medicines. Reports involving paternal exposure should record timing, relevant partner exposure and outcome without implying causation from chronology alone.

Fertility effects, sexual functioning, hot flushes and other endocrine outcomes require attribution that considers both enzalutamide and any concurrent ADT. Long treatment durations also increase the opportunity for drug interactions and age-related illness. Periodic treatment review is a clinical practice recommendation; it must not be represented as a newly invented fixed regulatory reporting schedule.

12. Drug interactions: a bidirectional pharmacovigilance problem

Enzalutamide may act as the victim of a pharmacokinetic interaction or as its perpetrator. Strong CYP2C8 inhibitors can increase its exposure, while strong CYP3A4 inducers can lower exposure. Separately, because enzalutamide induces CYP3A4, CYP2C9 and CYP2C19, it may reduce concentrations of other drugs metabolised by those pathways. The US label advises avoiding selected combinations or making specified dose adjustments when unavoidable [1]. The exact current local product information and specialist interaction review should determine clinical decisions.

Interaction pattern Possible consequence Follow-up priority
Strong CYP2C8 inhibitor added Increased enzalutamide/active-metabolite exposure Name, dose, dates, toxicity chronology
Strong CYP3A4 inducer added Reduced enzalutamide exposure Treatment history, disease markers, adherence
Enzalutamide plus sensitive CYP3A4/2C9/2C19 substrate Reduced co-medication effect or altered active-metabolite exposure Substrate, clinical outcome, drug concentrations where available
Antiseizure medicine or another medicine affecting seizure threshold Competing or interacting neurological risks Complete medicine list, seizure history, chronology
Multiple medicines in an older patient Adverse-event and therapeutic-failure confounding Prescription reconciliation, dispensing records

For a suspected loss of efficacy of a co-medication, ask whether the co-medication was started before or after enzalutamide, whether the interaction is mechanistically plausible and whether the clinical deterioration has a better explanation. For a suspected enzalutamide adverse reaction after a new inhibitor, document the start and stop dates of both drugs and the persistence of enzalutamide exposure. A pharmacokinetic mechanism supports an interaction hypothesis but is not proof that a particular patient's event was caused by it.

Digoxin laboratory assay interference: an analytical, not necessarily pharmacological, event

The US prescribing information revised in December 2025, retained in the July 2026 label, adds a warning that enzalutamide can interfere with certain digoxin immunoassays, including chemiluminescent microparticle immunoassays, producing falsely elevated measured digoxin concentrations [1]. The label instructs notification of the laboratory so an appropriate assay method can be used when the patient receives both drugs.

This matters because a spurious laboratory value can prompt an unnecessary digoxin dose change or a false diagnosis of toxicity. The report should distinguish analytical interference from an actual change in digoxin exposure or clinical toxicity. Record the assay platform, sample timing, laboratory confirmation method, symptoms, ECG, renal function, digoxin regimen and whether any clinical action was taken. A laboratory signal without an adverse medical outcome may still be a valuable product-safety issue, but it is not automatically a valid adverse-reaction ICSR.

13. Case assessment in practice

A pharmacovigilance intake process should capture the suspected medicine, reporter, identifiable patient and suspected reaction according to applicable ICSR criteria, and then pursue clinically meaningful follow-up under the relevant jurisdiction's reporting rules [15]. The additional fields below are recommendations for better medical evaluation, not new statutory validity elements.

Reported problem Essential medical detail Attribution traps
Seizure Witnessed description, prior seizures, brain imaging when relevant, metabolic results, co-medications Tumour-related brain disease or another provoking factor
PRES MRI, neurological findings, BP, differential diagnosis Labelling every headache or seizure as confirmed PRES
Ischaemic event ECG, troponin, coronary diagnosis, cardiovascular history, ADT Age, diabetes, smoking and pre-existing coronary disease
Fall or fracture Circumstances, imaging, bone disease, mobility, concomitant sedatives Metastatic skeletal disease and ADT-related bone loss
Choking/dysphagia Product form/strength, swallowing history, intervention Confusing mechanical administration risk with systemic toxicity
Digoxin assay anomaly Assay platform, confirmatory method, clinical signs False-positive laboratory result interpreted as toxicity
Disease progression PSA/imaging chronology, baseline disease state, ADT, adherence, interacting drugs Natural progression presented as confirmed drug failure

Illustrative case: a suspected interaction presenting as treatment failure

A patient on long-term enzalutamide develops worsening control of a separate condition after a new medicine is prescribed. Medication reconciliation identifies a substrate whose concentration may be reduced by enzyme induction. The assessor needs the full regimen, timing, clinical endpoint and any measured drug levels before deciding whether the suspected interaction is credible. This is a hypothetical educational example, not a real case or an assertion that the interacting drug is contraindicated.

Illustrative case: a high digoxin result without matching symptoms

A patient receiving digoxin and enzalutamide has an unexpectedly elevated digoxin immunoassay result but no matching clinical evidence of toxicity. The laboratory identifies a potentially susceptible assay. A confirmatory method is sought before concluding that digoxin exposure increased. This hypothetical case demonstrates how analytical interference can create a false safety signal and why laboratory-method details belong in the report [1].

14. Signal detection, risk minimisation and evidence traceability

The same reported event can arise through different mechanisms: a fracture may reflect metastatic bone disease, ADT-associated osteoporosis, a fall or a drug contribution; a seizure may reflect neurological disease, concomitant medicines or enzalutamide exposure. Individual case assessment should preserve competing explanations while recognising serious labelled risks. A signal is a hypothesis requiring evaluation, not proof of causation.

For periodic and cumulative evaluation, stratify where feasible by disease state, duration of exposure, co-prescribed ADT, prior chemotherapy, age, formulation and relevant comorbidities. Disproportionality analyses and spontaneous-report counts are subject to stimulated reporting, incomplete denominators and confounding. They cannot independently provide incidence rates. Regulatory decisions may draw on trial evidence, post-marketing reports, observational data, product-use investigations and benefit–risk assessment.

In an EU pharmacovigilance system, GVP Module VI supplies guidance on collection, management and submission of suspected adverse-reaction reports, while the marketing authorisation holder's legal obligations arise from applicable EU legislation [15]. A recommended internal workflow is to link intake, coding, duplicate detection, follow-up, signal assessment, labelling review, risk-minimisation communication and documented governance decisions. Records should make clear what was known, when it was known, what was done and why. A local operational checklist is not itself an additional EU legal obligation.

15. Common interpretation errors

A recurring error is to call all enzalutamide regimens “hormonal therapy” without documenting whether ADT continued. Another is to cite the favourable metastasis-free survival results from EMBARK as proof of a statistically significant overall-survival benefit from monotherapy; the later analysis did not demonstrate that conclusion [12,13]. Trial-specific percentages are sometimes transferred into patients with different disease stage, age, comorbidity or concomitant therapy without explaining the limits of comparison.

Other errors are practical rather than statistical: recording only the INN when swallowing-related product dimensions matter; interpreting a potentially false digoxin assay as definite toxicity; overlooking enzyme induction when a concomitant treatment becomes less effective; or equating a seizure with confirmed PRES without the diagnostic evidence. Each can be reduced through product traceability and structured medical follow-up.

16. Key takeaways

Enzalutamide arose from AR-resistance research and achieved progressively broader authorisation through distinct clinical trials. AFFIRM, PREVAIL, PROSPER, ARCHES, ENZAMET and EMBARK address different populations, comparators and endpoints. The 2025 EMBARK overall-survival update supports a survival advantage for enzalutamide plus leuprolide, not a statistically established survival advantage for enzalutamide monotherapy over leuprolide alone.

Important safety domains include seizures and PRES, ischaemic heart disease, hypertension, falls and fractures, hypersensitivity, embryo-fetal toxicity, and swallowing problems associated with product size. The 2026 US label also highlights digoxin immunoassay interference. Reliable pharmacovigilance depends on precise disease context, product identification, treatment chronology, competing causes and appropriate laboratory interpretation—not merely on the presence of a familiar adverse-event term.

References

  1. US National Library of Medicine, DailyMed. Xtandi (enzalutamide) capsules and tablets: US prescribing information. Updated 28 July 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf
  2. European Medicines Agency. Xtandi: European public assessment report and current product information. Original authorisation 21 June 2013; English product information updated 29 July 2026. https://www.ema.europa.eu/en/medicines/human/EPAR/xtandi
  3. European Commission. Union Register of medicinal products: Xtandi, EU/1/13/846. https://ec.europa.eu/health/documents/community-register/html/h846.htm
  4. Memorial Sloan Kettering Cancer Center. Charles L. Sawyers: publications and antiandrogen research history. https://www.mskcc.org/research-areas/labs/charles-sawyers/publications
  5. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787–790. doi:10.1126/science.1168175. https://pubmed.ncbi.nlm.nih.gov/19359544/
  6. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy (AFFIRM). N Engl J Med. 2012;367:1187–1197. doi:10.1056/NEJMoa1207506. https://doi.org/10.1056/NEJMoa1207506
  7. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy (PREVAIL). N Engl J Med. 2014;371:424–433. doi:10.1056/NEJMoa1405095. https://doi.org/10.1056/NEJMoa1405095
  8. Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer (PROSPER). N Engl J Med. 2018;378:2465–2474. doi:10.1056/NEJMoa1800536. https://doi.org/10.1056/NEJMoa1800536
  9. Sternberg CN, Fizazi K, Saad F, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer (PROSPER overall survival). N Engl J Med. 2020. https://pubmed.ncbi.nlm.nih.gov/32469184/
  10. Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized phase III study of ADT with enzalutamide or placebo in metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019. doi:10.1200/JCO.19.00799. https://doi.org/10.1200/JCO.19.00799
  11. Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer (ENZAMET). N Engl J Med. 2019. doi:10.1056/NEJMoa1903835. https://doi.org/10.1056/NEJMoa1903835
  12. Freedland SJ, de Almeida Luz M, De Giorgi U, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer (EMBARK). N Engl J Med. 2023. doi:10.1056/NEJMoa2303974. https://doi.org/10.1056/NEJMoa2303974
  13. Freedland SJ, et al. Improved survival with enzalutamide in biochemically recurrent prostate cancer (EMBARK overall survival). N Engl J Med. Published 19 October 2025. doi:10.1056/NEJMoa2510310. https://doi.org/10.1056/NEJMoa2510310
  14. UK electronic medicines compendium. Enzalutamide Astellas 40 mg film-coated tablets: Summary of Product Characteristics. Updated 1 April 2026. https://www.medicines.org.uk/emc/product/10318/smpc
  15. European Medicines Agency. Good pharmacovigilance practices (GVP): Module VI (Rev. 2), collection, management and submission of reports of suspected adverse reactions. Effective 22 November 2017; consult the GVP landing page for later revisions or related guidance. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/good-pharmacovigilance-practices-gvp

Regulatory Note

Evidence review date: 23 October 2026. This article distinguishes current US product labelling (DailyMed, 28 July 2026), EU marketing-authorisation scope (European Commission and EMA product information updated 29 July 2026), clinical trial results and recommended pharmacovigilance practice. US dosing and laboratory-assay warnings are not automatically binding instructions for every EU presentation; national product information and applicable rules must be checked. Trial effect estimates are specific to the enrolled populations, comparators, endpoint definitions and follow-up. No combination-product sales or patient-use figures have been attributed to the single INN. Illustrative cases are fictional and do not represent actual safety reports.

Revision History

Last reviewed: 2026-10-23

QPPV.com